Ricardo Rodrigues

6PUBLICATIONS
10CO-AUTHORS
Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 01, 2026
Association of TP53 Mutational Status and Survival in Anaplastic Thyroid Cancer Treated with Dabrafenib Plus Trametinib.

|Sep 15, 2026
Macrophages as Drivers of Resistance to Dabrafenib Plus Trametinib Therapy in Anaplastic Thyroid Cancer.

|Feb 02, 2026
Anti-tumour effects of combined lenvatinib and EGFR Inhibition in advanced differentiated thyroid cancer cells.

Ricardo Rodrigues, Carolina Pires, Carmo Martins

|Sep 09, 2023
SPRY4 as a Potential Mediator of the Anti-Tumoral Role of Macrophages in Anaplastic Thyroid Cancer Cells.

Ana Teresa Pinto, Marta Pojo, Ricardo Rodrigues

|Feb 28, 2023
Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma.

João Roque, Tiago Nunes Silva, Catarina Regala

|Jan 18, 2023
Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.

Tiago Nunes da Silva, Ricardo Rodrigues, Ana Saramago

Pageof 1

Frequent Collaborators

2 joint publications

Valeriano Leite

1 joint publications

João Roque

1 joint publications

Ana Teresa Pinto

1 joint publications

Diana Pacheco Sousa